Artiva Biotherapeutics, Inc. (ARTV) Financials

ARTV Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 106.0 million 18.1 million
Dec. 31, 2025 130.9 million 21.0 million
Sept. 30, 2025 148.9 million 19.6 million
June 30, 2025 169.4 million 20.4 million

ARTV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -21.2 million 1.6 million
Dec. 31, 2025 -15.1 million 1.6 million
Sept. 30, 2025 -19.8 million 1.6 million
June 30, 2025 -24.0 million 1.5 million

ARTV Net Income

No data available :(

ARTV Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 86.8 million 7.2 million 10.3 million
Dec. 31, 2025 108.0 million 7.9 million 10.9 million
Sept. 30, 2025 123.0 million - 8.5 million
June 30, 2025 142.4 million - 13.2 million

ARTV Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 24.7 million
Dec. 31, 2025 24.4 million
Sept. 30, 2025 24.5 million
June 30, 2025 24.4 million

ARTV Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 242000 19.3 million 5.1 million -
Dec. 31, 2025 421000 17.0 million 4.9 million -
Sept. 30, 2025 600000 17.6 million 5.3 million -
June 30, 2025 1.1 million 17.9 million 4.9 million -

ARTV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 666000
Dec. 31, 2025 - 666000
Sept. 30, 2025 - 662000
June 30, 2025 - -

ARTV

Price: $10.03

52 week price:
1.55
14.53

Earnings Per Share: -3.55 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 237.5 million

Links: